Clinical management of metastatic colorectal cancer in the era of precision medicine
F Ciardiello, D Ciardiello, G Martini… - CA: a cancer journal …, 2022 - Wiley Online Library
Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …
Evolving therapeutic landscape of advanced hepatocellular carcinoma
C Yang, H Zhang, L Zhang, AX Zhu… - Nature reviews …, 2023 - nature.com
Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …
A large proportion of patients with HCC are diagnosed at advanced stages and are only …
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
Colorectal cancer (CRC) is the third most common cancer worldwide, with 1.1 million new
cases per year, and is the second leading cause of cancer death. 1 CRC occurs more …
cases per year, and is the second leading cause of cancer death. 1 CRC occurs more …
[HTML][HTML] Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Background Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has
shown clinical activity in pretreated patients with several tumor types, including colorectal …
shown clinical activity in pretreated patients with several tumor types, including colorectal …
Rational combinations of targeted cancer therapies: background, advances and challenges
H Jin, L Wang, R Bernards - Nature Reviews Drug Discovery, 2023 - nature.com
Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …
[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …
strong evidence base for use in patients with cancer. The European Society for Medical …
[HTML][HTML] Effective drug combinations in breast, colon and pancreatic cancer cells
Combinations of anti-cancer drugs can overcome resistance and provide new treatments,.
The number of possible drug combinations vastly exceeds what could be tested clinically …
The number of possible drug combinations vastly exceeds what could be tested clinically …
Treatment of metastatic colorectal cancer: ASCO guideline
PURPOSE To develop recommendations for treatment of patients with metastatic colorectal
cancer (mCRC). METHODS ASCO convened an Expert Panel to conduct a systematic …
cancer (mCRC). METHODS ASCO convened an Expert Panel to conduct a systematic …
[HTML][HTML] Translational advances in pancreatic ductal adenocarcinoma therapy
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …
detected at advanced stages, limiting treatment options to systemic chemotherapy with …
The coming decade in precision oncology: six riddles
High-throughput methods to investigate tumour omic landscapes have quickly catapulted
cancer specialists into the precision oncology era. The singular lesson of precision oncology …
cancer specialists into the precision oncology era. The singular lesson of precision oncology …